Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma.
Multicentre Comparison of the Toxicity and Effectiveness of Lobaplatin-Based Versus Cisplatin-Based Adjuvant Chemotherapy in Oesophageal Carcinoma.
复制标题
DOI：
10.3389/fonc.2021.668140
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Xing W
中科院分区：
文献类型：
--
作者：
Zheng Y;Li Y;Liu X;Sun H;Liang G;Hu J;Li L;Xing W
洛铂（LBP）是第三代顺铂衍生物，在之前的报道中已在食管鳞状细胞癌（ESCC）中显示出良好的活性和很少的副作用。我们比较了 LBP 加多西他赛与顺铂加多西他赛作为 ESCC 患者辅助化疗的效果，以确定对总生存 (OS) 和毒性的影响。使用倾向评分匹配 (PSM) 与 Medicine-LinkDoc 数据库进行了一项多中心回顾性研究。选取2013年1月至2016年12月期间诊断为II-III期食管鳞癌并接受辅助化疗（顺铂加多西他赛或LBP加多西他赛）的患者选自中国6个中心。有 733 名符合条件的 ESCC 患者。 PSM（1:1 比例）后，剩下 458 名患者。顺铂组和LBP组的5年OS率分别为25.9%和23.6%（P=0.457）。白细胞减少症（III-IV/I-II/0级：2.62%/34.5%/59.39% vs 5.24%/43.23%/45.85%；P=0.0176），中性粒细胞减少症（III-IV/I-II/0级：6.55%/37.56%/51.09% vs 4.37%/53.28%/36.34%；P=0.0015），肾毒性（I-II/0级：13.97%/76.86% vs 26.64%/65.94%；P<0.001）和胃肠道症状（III-IV/I-II/0级：2.18%/54.59%/32.31%）顺铂组的发生频率为 6.55%/65.07%/20.88%；P=0.0011）。与顺铂联合多西他赛相比，LBP联合多西他赛提供了相同的生存获益，但骨髓抑制和胃肠道症状的副作用较低。 LBP联合多西紫杉醇可能是食管鳞癌辅助化疗的一种选择。洛铂或顺铂在食管癌辅助化疗中的应用，标识符 NCT03413436。
Lobaplatin (LBP), a third-generation cisplatin derivative has shown promising activity and few side effects in oesophageal squamous cell carcinoma (ESCC) in previous reports. We compared LBP plus docetaxel with cisplatin plus docetaxel as adjuvant chemotherapy in ESCC patients to determine the effects on overall survival (OS) and toxicity. A multicentre retrospective study was performed using propensity score matching (PSM) with the Medicine-LinkDoc database. Patients diagnosed with stage II-III ESCC treated with adjuvant chemotherapy (cisplatin plus docetaxel or LBP plus docetaxel) between January 2013 and December 2016 were selected from 6 centres in China. There were 733 eligible ESCC patients. After PSM (1:1 ratio), 458 patients remained. The 5-year OS rates of the cisplatin and LBP groups were 25.9% and 23.6%, respectively (P=0.457). Leukopenia (grade III-IV/I-II/0: 2.62%/34.5%/59.39% versus 5.24%/43.23%/45.85%; P=0.0176), neutropenia (grade III-IV/I-II/0: 6.55%/37.56%/51.09% versus 4.37%/53.28%/36.34%; P=0.0015), nephrotoxicity (grade I-II/0: 13.97%/76.86% versus 26.64%/65.94%; P<0.001) and gastrointestinal symptoms (grade III-IV/I-II/0: 2.18%/54.59%/32.31% versus 6.55%/65.07%/20.88%; P=0.0011) were more frequent in the cisplatin group. Compared with cisplatin plus docetaxel, LBP plus docetaxel provided the same survival benefits but lower side effects of myelosuppression and gastrointestinal symptoms. LBP plus docetaxel might be a choice for adjuvant chemotherapy in ESCC. Lobaplatin or Cisplatin in Adjuvant Chemotherapy for Oesophageal Carcinoma, identifier NCT03413436.
登录
查看更多内容
影响因子：
4.7
作者：
Zhang, Hongming;Chen, Runzhe;Chen, Jibei
通讯作者：
Chen, Jibei
影响因子：
8.8
作者：
Gietema, J A;de Vries, E G;Sleijfer, D T;Willemse, P H;Guchelaar, H J;Uges, D R;Aulenbacher, P;Voegeli, R;Mulder, N H
通讯作者：
Mulder, N H
影响因子：
4.6
作者：
Zhai X;Zheng Q;Yang L;Zhu Y;Li J;Liu Y;Wang Z
通讯作者：
Wang Z
影响因子：
--
作者：
Wang, Nan;Lv, Yin-Zhang;Li, Jia-Rui
通讯作者：
Li, Jia-Rui
影响因子：
2.6
作者：
Miyawaki, Yutaka;Nakajima, Yasuaki;Kawano, Tatsuyuki
通讯作者：
Kawano, Tatsuyuki